Literature DB >> 31527383

Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration.

Angela Lamarca1,2, Jorge Barriuso3,4, Mairéad G McNamara3,4, Richard A Hubner3,4, Prakash Manoharan5, Wasat Mansoor3,4, Juan W Valle3,4.   

Abstract

Entities:  

Year:  2019        PMID： 31527383     DOI： 10.1159/000503392

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN： 0028-3835            Impact factor:   4.914


× No keyword cloud information.
  2 in total

Review 1.  Chemotherapy in NEN: still has a role?

Authors:  Paula Espinosa-Olarte; Anna La Salvia; Maria C Riesco-Martinez; Beatriz Anton-Pascual; Rocio Garcia-Carbonero
Journal:  Rev Endocr Metab Disord       Date:  2021-04-11       Impact factor: 9.306

2.  A Retrospective Trail Investigating Temozolomide Neoadjuvant Chemotherapy Combined with Radiotherapy in Low-Grade Pituitary Tumors.

Authors:  Jie Cui; Jianbo Shen; Xiaohong Ru; Zhihua Tian; Zhibin Duan; Guiping Chen; Min Li
Journal:  J Oncol       Date:  2022-03-25       Impact factor: 4.375
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.